



LKT Laboratories, Inc.

Rivaroxaban

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID R3584

CAS No. 366789-02-8

Chemical Name

Synonym

Formula $C_{19}H_{18}ClN_3O_5S$

Formula Wt. 435.88

Melting Point


Purity $\geq 98\%$

Solubility MeOH

Store Temp Ambient

Ship Temp Ambient

Description Rivaroxaban is an orally bioavailable oxazolidone derivative that acts as an antithrombotic/anticoagulant, reversibly inhibiting factor Xa. Rivaroxaban directly binds to the S1 and S4 pockets of factor Xa and inhibits both free and clot-bound forms. In vitro models indicate that rivaroxaban may also exert inhibitory effects during the early stages of bone formation, as it inhibits hormone-stimulated modulation of ER and 1-OHase expression as well as DNA synthesis, creatine kinase activity, and alkaline phosphatase activity.



Bulk quantities available upon request

Product ID	Size
R3584	1 mg
R3584	5 mg
R3584	25 mg

References Kreutz R. Pharmacokinetics and Pharmacodynamics of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor. *Curr Clin Pharmacol.* 2013 Nov 11. [Epub ahead of print]. PMID: 24218999.

Somjen D, Katzburg S, Gigi R, et al. Rivaroxaban, a direct inhibitor of the coagulation factor Xa interferes with hormonal-induced physiological modulations in human female osteoblastic cell line SaOS2. *J Steroid Biochem Mol Biol.* 2013 May;135:67-70. PMID: 23333933

Gigi R, Salai M, Dolkart O, et al. The effects of direct factor Xa inhibitor (Rivaroxaban) on the human osteoblastic cell line SaOS2. *Connect Tissue Res.* 2012;53(6):446-50. PMID: 22800431.

Samama MM. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants. *Thromb Res.* 2011 Jun;127(6):497-504. PMID: 20888031.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.